Pure Global
NCT05429762

Effect of Tusamitamab Ravtansine on QTc Interval in Participants With Metastatic Solid Tumors

Open-label Study Evaluating the Effect of Tusamitamab Ravtansine on the QTc Interval in Participants With Metastatic Solid Tumors
Sanofi·Phase 1·ClinicalTrials.gov·drugNot yet recruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Neoplasm
Drug/Device/Intervention
Tusamitamab ravtansine
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
Sanofi
Timeline & enrollment
Phase
Phase 1
Start date
Sep 30, 2022
End date
Nov 04, 2024
Enrollment
50 participants
Primary outcome

Change from baseline in QT-interval corrected (QTcF) centrally assessed

Summary

This is a Phase1, single-arm study for treatment. This is a prospective multicenter,
 multinational, open-label study to assess the effect of tusamitamab ravtansine on the QT
 interval in participants with metastatic colorectal cancer (CRC), nonsquamous non small cell
 lung cancer (NSQ NSCLC), or gastric/ gastroesophageal junction (GEJ) adenocarcinoma for which
 in the judgement of the Investigator, no standard alternative therapy is available.

ICD-10 classifications
NeoplasmsBenign neoplasmsIn situ neoplasmsPersonal history of other neoplasmsBenign neoplasm: Other specified sites
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT05429762
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT05429762 through Pure Global AI's free database. This Phase 1 trial is sponsored by Sanofi and is currently Not yet recruiting. The study focuses on Neoplasm. Target enrollment is 50 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.